← Ionis Pharmaceuticals, Inc. (IONS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Ionis Pharmaceuticals, Inc. (IONS)
Pharmaceutical Preparations · market cap $7.2B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Ionis Pharmaceuticals (IONS) is a Carlsbad-based antisense RNA therapeutics pioneer with a sprawling pipeline spanning rare disease, cardiometabolic, and neurological indications. The company carries a $10.6B market cap but reported a net loss of $381M in 2025 on $944M revenue, holds only $173M cash against $579M net debt, and faces an alarming ~0.7-month reported cash runway — a critical financial constraint that frames every near-term catalyst discussion. A Phase 3 readout on July 9, 2026 was negative, while a regulatory event on July 2 was positive, setting a mixed near-term backdrop.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 3 · Donidalorsenimp 9/10
- 2027-02-28 (est.)Phase 1imp 6/10
- 2027-03-15 (est.)Phase 3 · Olezarsenimp 9/10
- 2027-06-15 (est.)Phase 3 · Olezarsenimp 9/10
- 2027-08-15 (est.)Phase 3 · ION582imp 9/10
- 2027-08-15 (est.)Phase 2 · ION582imp 7/10
- 2027-09-15 (est.)Phase 2 · ION440imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Volanesorsen | Phase 3 | Familial Chylomicronemia Syndrome |
| Olezarsen | Phase 3 | Familial Chylomicronemia Syndrome |
| ISIS-APO(a)Rx | Phase 2 | Elevated Lipoprotein(a) |
| ION224 | Phase 2 | Steatohepatitis, Nonalcoholic |
| ISIS 443139 10 mg | Phase 2 | Huntington's Disease |
| Inotersen | Phase 3 | FAP |
| ISIS 113715 | Phase 2 | Type 2 Diabetes Mellitus |
| ISIS-GCCRRx | Phase 2 | Type 2 Diabetes Mellitus |
| ION582 | Phase 3 | Angelman Syndrome |
| ION363 | Phase 3 | Amyotrophic Lateral Sclerosis |
| ISIS EIF4E Rx | Phase 2 | Castrate-Resistant Prostate Cancer |
| ISIS 757456 | Phase 2 | Mild Hypertension |
| ISIS 416858 | Phase 2 | End-stage Renal Disease (ESRD) |
| ION717 | Phase 2 | Prion Disease |
| ISIS-PTP1BRx | Phase 2 | Type 2 Diabetes Mellitus |
| zilganersen | Phase 3 | Alexander Disease |
| ION904 | Phase 2 | Hypertension |
| ISIS 104838 | Phase 2 | Rheumatoid Arthritis |
| IONIS-DMPKRx | Phase 2 | Myotonic Dystrophy Type 1 |
| Alicaforsen | Phase 3 | Ulcerative Colitis |
Price & technical context
3-month
-46.2%
6-month
-41.4%
12-month
-33.1%
52-wk range
$43.81–$86.50
vs 50-day MA
-18.7%
vs 200-day MA
-37.6%
Realized vol
46.7%
Max drawdown
-49.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IONS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.